Why Pfizer’s Stock Price Isn’t Reflecting Its True Value (NYSE:PFE)

1. Pfizer's EPS and revenue exceeded expectations, driven by strong anti-cancer sales. 2. Xtandi sales rose 79.9% YoY, totaling $565 million in Q4 2024. 3. Vyndaqel family's sales grew over 60% YoY, aiding Pfizer's financial performance. 4. Pfizer reduced net debt by $4.65 billion in the last 12 months. 5. The stock is deemed attractive for income-oriented investors amidst market pressure.